Best of ASCO - 2014 Annual Meeting



Local-Regional Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies.

Scott Joseph Antonia


A deep-learning radiomics model for predicting survival in early-stage non-small cell lung cancer.

Tafadzwa Lawrence Chaunzwa


A gene expression signature to characterize human lung adenocarcinoma cancer stem cells.

Alejandro Herreros-Pomares


A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).

Tina Cascone


A phase I//II study of computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiotherapy for locally advanced peripheral non-small cell lung cancer.

Li Xiang


A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403)—Long term follow-up results.

Yasushi Nagata


A real-world observational study to explore clinical characteristics of Chinese patients with T1 non-small cell lung cancer complicated with lymph metastases.

Feng Jiang


An imaging/biology correlation study between radiomics features and anaplastic lymphoma kinase (ALK) mutational status in a uniform Chinese cohort of locally advanced lung adenocarcinomas.

Meilin Jiang


Association between certain NSCLC driver mutations and sensitivity markers for chemotherapy or PD-(L)1 inhibition: A large-sample analysis.

Wenhua Liang


Association between hospital volume, treatment patterns, and overall survival (OS) of patients with stage 3A non-small cell lung cancer (NSCLC).

Sri Harsha Tella


Big data for supporting precision medicine in lung cancer patients.

Maria Torrente


Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase II study.

Seiji Niho


Circulating tumor DNA (ctDNA) as a marker of minimal residual disease (MRD) in localized non-small cell lung carcinoma (NSCLC).

Nicholas I. Simon


Clinical characteristics of patients with lymph skip metastases and prognoses of Chinese patients with pN2 non-small cell lung cancer.

Xin Li


Clinical relevance of intratumoural immune cell composition in non-small cell lung cancer.

Xuetao Li


Clinical significance and next-generation sequencing of Chinese pulmonary sarcomatoid carcinoma.

Jun Chen


Comparative evaluation of effectiveness of neoadjuvant chemoimmunotherapy (nPCIT) for non-small cell lung cancer (NSCLC).

Yuri Lazutin


Comparison between the microbiota in lung tumor and adjacent normal tissues in lung cancer patients.

Qixing Mao


Comparison of clinical characteristics and prognoses of patients with T1 non-small cell lung cancer and small cell lung cancer in a Chinese real-world study.

Xu Jinming


Comparison of surgeries plus perioperative and postoperative chemotherapies in Chinese pN2 patients with non-small cell lung cancer: A real-world observational study.

Jinbo Zhao


Co-mutations in surgically resected and EGFR mutated lung adenocarcinoma: A subset analysis of the large prospective cohort study.

Kenji Sawa


Concept to clinic: An open-innovation crowdsourcing challenge to develop AI-enabled software for lung cancer detection.

Guneet Walia


Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients.

Angel Qin


Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer.

Haruhisa Matsuguma


Development and validation of a molecule based nomogram to predict relapse in stage I NSCLC.

Qixing Mao


Differential diagnosis of pulmonary enteric adenocarcinoma (PEAC) with the assistance of next generation sequencing.

Jie Zhang


Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection.

Greg Andrew Durm


Effectiveness and safety of lobectomy and sublobar dissection in Chinese elderly patients with non-small cell lung cancer: A real-world observational study.

Zhenrong Zhang


Effectiveness and safety of systematic and selective lymphadenectomies in Chinese patients with non-small cell lung cancer who received sublobar resection.

Min Zhu


Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.

Liming Sheng


Endogenous arginase 2 as a biomarker for PEGylated arginase 1 treatment in squamous cell lung carcinoma xenograft models.

James C. M. Ho


Evaluating PD-L1 status and its correlation with clinical features in surgically resected lung adenocarcinoma patients: Comparison of tissue microarrays and whole tissue section.

Hsu-Ching Huang


Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemo-radiation in stage III NSCLC. SLCG 10/02.

Mariano Provencio-Pulla


Genome-wide identification and characterization of aberrant tRNA-derived RNA fragments in non-small cell lung cancer.

Lin Yang


Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.

Geoffrey R. Oxnard


Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.

Ernest Nadal


Hypercalcemia in malignancy: An inpatient analysis.

Divya Asti


Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06).

Hervé Le Caer


Impact of corticosteroid administration on outcomes following stereotactic ablative radiotherapy for non-small cell lung cancer.

Hongqi LI


Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).

Akihiro Tamiya


Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC.

Jason Francis Lester


Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.

Changchuan Jiang


Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT.

Yasuhiro Tsutani


Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.

Ramesh Rengan


Long-term survival after salvage SBRT for recurrent or secondary non-small cell lung cancer after prior surgery or radiation therapy.

Chunyu He


Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.

Feng-Ming Spring Kong


Microwave ablation plus recombinant human endostatin (endostar) versus microwave ablation alone in inoperable stage I non small cell lung cancer.

Min Meng


Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.

Martin Frueh


NanoPac inhalation treatment of NSCLC in a nude rat orthotopic lung cancer model.

Gere Dizerega


Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).

Catherine A. Shu


Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

Valerie W. Rusch


Neutrophil to lymphocyte ratio (NLR) as a useful prognostic marker for survival in patients with locally advanced (stage III) non-small cell lung cancer (NSCLC).

Ali Tahir


New generation of cancer stem cells inhibitors in non-small cell lung cancer.

Héctor Amado Labrador


NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).

Dolores Isla


PD-L1 expression in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

Nobuaki Mamesaya


Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.

Helen J. Ross


Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Greg Andrew Durm


Pragmatic study of a lymph node (LN) collection kit for non-small cell lung cancer (NSCLC) resection.

Raymond U. Osarogiagbon


Prognostic factors for survival in locally advanced NSCLC treated with concurrent chemo- radiation: An institutional analysis.

Sowmini Medavaram


Prognostic sıgnificance of PD-L1 in stage II/III non-small cell lung cancer.

Deniz Tural


Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.

Chen Hu


Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

Hiran C. Fernando


Relationship between pre-diagnosis tumor board and time interval from imaging to staging in lung cancer.

Prashanth Thalanayar Muthukrishnan


Routine use of a modest next generation sequencing panel provides additional clinically useful data beyond single gene testing in non-small cell lung cancer and is fit for purpose as a clinical assay: Collated data from a single molecular diagnostic laboratory.

David Allan Moore


Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

Solange Peters


SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Sacha Rothschild


Significance of aromatase-estrogen receptor axis in EGFR status of lung adenocarcinoma.

Kazumi Tanaka


Surgical treatments of Chinese patients with lung malignant tumors.

Hu Liao


Survival in right-sided versus left-sided stage IB-IIIA non-small cell lung cancer patients.

Ziping Wang


Survival in the population-based Mid-South Quality of Surgical Resection (MSQSR) Cohort.

Matthew Smeltzer


The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.

Lecia V. Sequist


The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).

Hadas Sorotsky


The prognostic significance of ATRX in pulmonary carcinoid tumors.

Hao Xie


Time to treatment and survival in veterans with stage I-IIIA lung cancer eligible for curative intent therapy.

Duc Ha


Trends in non-small cell lung cancer biomarker testing rates in the US and Western Europe from 2014-2017.

Bijal Shah-Manek


tRNA modification profiles of non-small cell lung cancer (NSCLC).

Rihong Zhai


Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage Ⅲa non-small cell lung cancer.

Yan Xu


Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.

David E. Gerber


Using deep-learning radiomics to predict lung cancer histology.

Tafadzwa Lawrence Chaunzwa